Jacobs Levy Equity Management, Inc Biomarin Pharmaceutical Inc Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $9.58 Million - $11 Million	-128,121 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $7.44 Million - $8.36 Million	-98,590 Reduced 43.49%	128,121 $10.7 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $2.36 Million - $2.87 Million	31,602 Added 16.2%	226,711 $17.1 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $271,270 - $336,987	3,736 Added 1.95%	195,109 $17.1 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $13.8 Million - $25.1 Million	191,373 New	191,373 $14.6 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $7.07 Million - $8.93 Million	-104,970 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$80.35 - $93.9 $3.36 Million - $3.93 Million	41,856 Added 66.32%	104,970 $8.99 Million
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $5.31 Million - $6.22 Million	63,114 New	63,114 $5.61 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $345,631 - $412,203	-4,450 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$80.76 - $95.13 $17,767 - $20,928	-220 Reduced 4.71%	4,450 $397,000
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $376,402 - $443,416	4,670	4,670 $435,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.